Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women
| Autor: | Xuan Chen, Jianyang Li, Sainan Chen, Jingwen Huang, Yunjin Ye, Lihua Xie, Shengqiang Li, Juan Chen, Jirong Ge |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system Bone density Osteoporosis 030209 endocrinology & metabolism 03 medical and health sciences 0302 clinical medicine Absorptiometry Photon Rheumatology Bone Density Internal medicine medicine Blood test Humans Orthopedics and Sports Medicine Femur Osteoporosis Postmenopausal 030304 developmental biology Femoral neck Aged Bone mineral Aged 80 and over 0303 health sciences medicine.diagnostic_test business.industry Middle Aged medicine.disease Osteopenia Postmenopause Endocrinology medicine.anatomical_structure Fracture Leukocytes Mononuclear Cytokines Female lcsh:RC925-935 business Cardiotrophin like cytokine factor 1 Research Article |
| Zdroj: | BMC Musculoskeletal Disorders BMC Musculoskeletal Disorders, Vol 22, Iss 1, Pp 1-9 (2021) |
| ISSN: | 1471-2474 |
| Popis: | BackgroundRecent research has suggested that cardiotrophin-like cytokine factor 1 (CLCF1) may be an important regulator of bone homeostasis. Furthermore, a whole gene chip analysis suggested that the expression levels of CLCF1 in the peripheral blood mononuclear cells (PBMCs) were downregulated in postmenopausal women with osteoporosis. This study aimed to assess whether the expression levels of CLCF1 in PBMCs can reflect the severity of bone mass loss and the related fracture risk.MethodsIn all, 360 postmenopausal women, aged 50 to 80 years, were included in the study. A survey to evaluate the participants’ health status, measurement of bone mineral density (BMD), routine blood test, and CLCF1 expression level test were performed.ResultsBased on the participants’ bone health, 27 (7.5%), 165 (45.83%), and 168 (46.67%) participants were divided into the normal, osteopenia, and osteoporosis groups, respectively. CLCF1 protein levels in the normal and osteopenia groups were higher than those in the osteoporosis group. While theCLCF1mRNA level was positively associated with the BMD of total femur (r= 0.169,p= 0.011) and lumbar spine (r= 0.176,p= 0.001), the protein level was positively associated with the BMD of the lumbar spine (r= 0.261,pr= 0.236,p= 0.001), greater trochanter (r= 0.228,p= 0.001), and Ward’s triangle (r= 0.149,p= 0.036). Both the mRNA and protein levels were negatively associated with osteoporosis development (r= − 0.085,p= 0.011 andr= − 0.173,p= 0.014, respectively). The association between CLCF1 protein level and fracture risk was not significant after adjusting for BMD.ConclusionsTo our knowledge, this is the first clinical study to show that CLCF1 expression levels in the PBMCs of postmenopausal women can reflect the amount of bone mass or the severity of bone mass loss. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink